Amgen (BUE:AMGN) Other Current Receivables : ARS243,314 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Amgen Other Current Receivables?

Amgen's Other Current Receivables for the quarter that ended in Dec. 2023 was ARS243,314 Mil.

Amgen's quarterly Other Current Receivables stayed the same from Jun. 2023 (ARS0.00 Mil) to Sep. 2023 (ARS0.00 Mil) but then increased from Sep. 2023 (ARS0.00 Mil) to Dec. 2023 (ARS243,314.00 Mil).

Amgen's annual Other Current Receivables increased from Dec. 2021 (ARS95,334.56 Mil) to Dec. 2022 (ARS138,981.85 Mil) and increased from Dec. 2022 (ARS138,981.85 Mil) to Dec. 2023 (ARS243,314.00 Mil).

Amgen Other Current Receivables Historical Data

The historical data trend for Amgen's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Other Current Receivables Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Receivables

Get a 7-Day Free Trial

95,334.56

138,981.85

243,314.00

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Current Receivables	Get a 7-Day Free Trial															138,981.85	-	-	-	243,314.00

Amgen Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

Amgen Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Amgen's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (BUE:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BUE:AMGN) » Definitions » Other Current Receivables

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.